Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > Big news can hit pr anytime

<< Previous

Bullboard Posts

Next >>

Comment by Alba1314on Aug 07, 2018 12:47pm

93 Views

Post# 28421826

RE:RE:Big news can hit pr anytime

Q2 Finincials and funding for Phase II/III study. Q2 results were posted last year on August 29th. That's not to say they couldnt be released earlier so really any time now. The funding is the big question. Thats what people are really waiting for. Phase I data is out and over with.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing